Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Focal Segmental Glomerulosclerosis Epidemiology Forecast Report

DelveInsight’s ‘Focal segmental glomerulosclerosis (FSGS)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the FSGS, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Focal segmental glomerulosclerosis (FSGS) Disease Understanding

Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed. The clinical features of FSGS are the features of nephrotic syndrome and include peripheral edema, marked proteinuria hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function. It may be found either as primary or secondary forms.

Primary FSGS sometimes has no identifiable cause or known etiology (idiopathic) and is linked to genetic mutations in podocyte-specific proteins, while secondary FSGS may occur in response to previous glomerular injury, glomerular hypertension, hypertrophy, drug toxicity, some malignancies or viral infections, obesity, and reduced renal mass.

FSGS is further classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion. The pathogenesis of FSGS is very complex; however, understanding basic mechanisms of podocyte injury is important not only for basic research but also for daily diagnostic pathology practice.

Focal segmental glomerulosclerosis (FSGS) Epidemiology

The FSGS epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted FSGS epidemiology segmented as the Total prevalence of FSGS, Gender-Specific cases of FSGS, and Clinical Subtype cases of FSGS. The report includes the prevalent scenario of FSGS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Focal segmental glomerulosclerosis (FSGS) Epidemiology

The epidemiology segment also provides the Focal segmental glomerulosclerosis (FSGS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of FSGS Associated in 7MM countries ranges from 202,687 in 2017.

• As per the estimates, the United States has the highest prevalent population of FSGS.

• Among the EU5 countries, Germany had the highest prevalent population of FSGS, followed by France. On the other hand, Spain had the lowest prevalent population with 12,805 cases in 2017.

Scope of the Report

• Focal segmental glomerulosclerosis (FSGS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• Focal segmental glomerulosclerosis (FSGS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Focal segmental glomerulosclerosis (FSGS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

• The report provides insight about the historical and forecasted patient pool of Focal segmental glomerulosclerosis (FSGS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan

• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population

• The report assesses the disease risk and burden and highlights the unmet needs of FSGS

• The report provides the segmentation of the Focal segmental glomerulosclerosis (FSGS) epidemiology by Prevalent Cases of Focal segmental glomerulosclerosis (FSGS) in 7MM

• The report provides the segmentation of the Focal segmental glomerulosclerosis (FSGS) epidemiology by gender-specific Prevalent Cases of Focal segmental glomerulosclerosis (FSGS) in 7MM

• The report provides the segmentation of the Focal segmental glomerulosclerosis (FSGS) epidemiology by clinical subtype based diagnosed Cases of Focal segmental glomerulosclerosis (FSGS) in 7MM


Report Highlights

• 11-Year Forecast of Focal segmental glomerulosclerosis (FSGS) epidemiology

• 7MM Coverage

• Total Prevalent Cases of Focal segmental glomerulosclerosis (FSGS)

• Prevalent Cases according to segmentation: Gender-specific Prevalence of FSGS

• Prevalent Cases according to segmentation: Clinical- subtype-specific Prevalence of FSGS

• Diagnosed cases of FSGS


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to FSGS?

• What are the key findings pertaining to the Focal segmental glomerulosclerosis (FSGS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?

• What would be the total number of patients of Focal segmental glomerulosclerosis (FSGS) across the 7MM during the forecast period (2017–2030)?

• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?

• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?

• What is the disease risk, burden and unmet needs of the FSGS?

• What are the currently available treatments of FSGS?


Reasons to buy

The Focal segmental glomerulosclerosis (FSGS) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Focal segmental glomerulosclerosis (FSGS) market

• Quantify patient populations in the global Focal segmental glomerulosclerosis (FSGS) market to improve product design, pricing, and launch plans

• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Focal segmental glomerulosclerosis (FSGS) therapeutics in each of the markets covered

• Understand the magnitude of Focal segmental glomerulosclerosis (FSGS) population by its Prevalence cases

• Understand the magnitude of Focal segmental glomerulosclerosis (FSGS) population by its Gender-specific cases

• Understand the magnitude of Focal segmental glomerulosclerosis (FSGS) population by its Clinical subtype-specific cases

• The Focal segmental glomerulosclerosis (FSGS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists

• The Focal segmental glomerulosclerosis (FSGS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation

• Disease Risk and Burden

• Risk of disease by the segmentation

• Factors driving growth in a specific patient population

Geographies Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017–2030

According to the United States, Renal Data Service (USRDS)-2005 documented data, it is reported that more than 7000 patients received ESRD therapy in the United States. The USRDS also demonstrates a dramatic increase in the incidence of ESRD due to FSGS, particularly over the last decade in the African American population.

Hull et al., reported that FSGS accounts for about 35% of cases of nephrotic syndrome in the US adults and 20–55% of cases in US children, with an estimated rate of 7 per 100,000.

Also, North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) shows that FSGS carries have the highest likelihood of progressing to end-stage renal disease (ESRD), exceeding the risk of hypoplasia, obstructive uropathy, and reflux nephropathy (from analysis of 6000 children with chronic kidney disease).

According to EMA, in 2018, FSGS was reported to affect around 2.6 per 10,000 people in European Union, which ensued to entitle FSGS as an orphan disease in Europe.

1 Key Insights

2 Executive summary

3 Key Organizations

4 Epidemiology Methodology

5 Focal Segmental Glomerulosclerosis (FSGS): Patient Overview at a Glance

5.1 Patient Share (%) Distribution of FSGS in 2017

5.2 Patient Share (%) Distribution of FSGS in 2030

6 Disease Overview: Focal Segmental Glomerulosclerosis

6.1 Introduction

6.2 Classification of FSGS

6.3 Signs and Symptoms

6.4 Histopathology

6.5 Etiology

6.6 Pathogenesis

6.7 Biomarkers

6.8 Diagnosis of FSGS

6.8.1 Differential Diagnosis

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 7MM Total Prevalent Population of Focal Segmental Glomerulosclerosis

7.3 Country Wise-Epidemiology of Focal Segmental Glomerulosclerosis

7.4 United States

7.4.1 Assumptions and Rationale

7.4.2 Prevalent Cases of Focal Segmental Glomerulosclerosis in the United States

7.4.3 Gender-specific Cases of Focal Segmental Glomerulosclerosis in the US

7.4.4 Type-specific Cases of Focal Segmental Glomerulosclerosis in the US

7.5 EU5

7.5.1 Assumptions and Rationale

7.6 Germany

7.6.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in Germany

7.6.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in Germany

7.6.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in Germany

7.7 France

7.7.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in France

7.7.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in France

7.7.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in France

7.8 Italy

7.8.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in Italy

7.8.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in Italy

7.8.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in Italy

7.9 Spain

7.9.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in Spain

7.9.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in Spain

7.9.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in Spain

7.1 United Kingdom

7.10.1 Prevalent Cases of Focal Segmental Glomerulosclerosis in the United Kingdom

7.10.2 Gender-specific Cases of Focal Segmental Glomerulosclerosis in the United Kingdom

7.10.3 Type-specific Cases of Focal Segmental Glomerulosclerosis in the UK

7.11 Japan

7.11.1 Assumptions and Rationale

7.11.2 Prevalent Cases of Focal Segmental Glomerulosclerosis in Japan

7.11.3 Gender-specific Cases of Focal Segmental Glomerulosclerosis in Japan

7.11.4 Type-specific Cases of Focal Segmental Glomerulosclerosis in Japan

8 Current Treatment Practices

8.1 Kidney Disease: Improving Global Outcomes- KDIGO Guideline: Idiopathic FSGS in adults

9 Unmet Needs

10 Appendix

11 Report Methodology

12 DelveInsight Capabilities

13 Disclaimer

14 About DelveInsight

15 Disclaimer 

Table 1: List of organization

Table 3: Characteristic clinical and pathology features of the six forms of FSGS

Table 4: Causes of focal segmental glomerulosclerosis

Table 5: Genes related to FSGS or nephrotic syndrome

Table 6: Diagnostic protein biomarker candidates for FSGS

Table 7: Prognostic candidate biomarkers

Table 8: Differential diagnoses of FSGS

Table 9: Prevalent Population of Focal Segmental Glomerulosclerosis in 7MM (2017–2030)

Table 10: Prevalent Cases of FSGS in the United States (2017–2030)

Table 11: Gender-specific cases of FSGS in the United States (2017–2030)

Table 12: Type-specific Cases of FSGS in the United States (2017–2030)

Table 13: Prevalent Cases of FSGS in Germany (2017–2030)

Table 14: Gender-specific cases of FSGS in Germany (2017–2030)

Table 15: Type-specific Cases of FSGS in Germany (2017–2030)

Table 16: Prevalent Cases of FSGS in France (2017–2030)

Table 17: Gender-specific cases of FSGS in France (2017–2030)

Table 18: Type-specific Cases of FSGS in France (2017–2030)

Table 19: Prevalent Cases of FSGS in Italy (2017–2030)

Table 20: Gender-specific cases of FSGS in Italy (2017–2030)

Table 21:Type-specific Cases of FSGS in Italy (2017–2030)

Table 22: Prevalent Cases of FSGS in Spain (2017–2030)

Table 23: Gender-specific cases of FSGS in Spain (2017–2030)

Table 24: Type-specific Cases of FSGS in Spain (2017–2030)

Table 25: Prevalent Cases of FSGS in the United Kingdom (2017–2030)

Table 26: Gender-specific cases of FSGS in the United Kingdom (2017–2030)

Table 27: Type-specific Cases of FSGS in the UK (2017–2030)

Table 28: Prevalent Cases of FSGS in Japan (2017–2030)

Table 29: Gender-specific cases of FSGS in Japan (2017–2030)

Table 30: Type-specific Cases of FSGS in Japan (2017–2030)

Figure 1: Epidemiology and Market Methodology

Figure 2: Focal Segmental Glomerulosclerosis

Figure 3: Common symptoms of FSGS

Figure 4: Histopathology of minimal change disease and focal segmental glomerulosclerosis

Figure 5: Pathogenesis of FSGS

Figure 6: Prevalent Population of Focal Segmental Glomerulosclerosis in 7MM (2017–2030)

Figure 7: Prevalent Cases of FSGS in the United States (2017–2030)

Figure 8: Gender-specific Prevalent Cases of FSGS in the US (2017–2030)

Figure 9: Type-specific Diagnosed Prevalent Cases of FSGS in the US (2017–2030)

Figure 10: Prevalent Cases of FSGS in Germany (2017–2030)

Figure 11: Gender-specific of FSGS in Germany (2017–2030)

Figure 12: Type-specific Cases of FSGS in Germany (2017–2030)

Figure 13: Prevalent Cases of FSGS in France (2017–2030)

Figure 14: Gender-specific Cases of FSGS in France (2017–2030)

Figure 15: Type-specific Cases of FSGS in France (2017–2030)

Figure 16: Prevalent Cases of FSGS in Italy (2017–2030)

Figure 17: Gender-specific Cases of FSGS in Italy (2017–2030)

Figure 18: Type-specific Cases of FSGS in Italy (2017–2030)

Figure 19: Prevalent Cases of FSGS in Spain (2017–2030)

Figure 20: Gender-specific Cases of FSGS in Spain (2017–2030)

Figure 21: Type-specific Cases of FSGS in Spain (2017–2030)

Figure 22: Prevalent Cases of FSGS in the United Kingdom (2017–2030)

Figure 23: Gender-specific Cases of FSGS in the United Kingdom (2017–2030)

Figure 24: Type-specific Cases of FSGS in the UK (2017–2030)

Figure 25: Prevalent Cases of FSGS in Japan (2017–2030)

Figure 26: Gender-specific Cases of FSGS in Japan (2017–2030)

Figure 27: Type-specific Cases of FSGS in Japan (2017–2030)

Figure 28: Treatment algorithm of FSGS

Figure 43: Market Size of FSGS in Japan, USD Millions (2017–2030)

Figure 44:Market Size of FSGS by Therapies in USD Million (2017–2030)

Forward to Friend

Need A Quote